CD4 and lymphoma: The recently detected DNMT3A mutation being reported by the French lymphoma study group in one single case of their series of CD4+ lymphoproliferation has hitherto not been described in PCFBCL, and thus might represent a discriminatory molecular feature if validated in further studies.